BioSpace News Archive

Advanced NanoTherapies, Inc., a privately-held medical device company committed to exploring nanotechnology for enhanced drug uptake and sustained retention, today announced it has closed on the final tranche of its seed-round financing for a total of $5.3 million

The Leukemia & Lymphoma Society of Canada and Loblaw Companies Limited are pleased to announce this year’s Give a Little, Help a Lot Light The Night campaign has raised $281,874 for Canadians affected by a blood cancer through in-store fundraising at its Superstore and Extra Food locations across the Western provinces and Ontario . Funds

Scott Thomson has been appointed CEO of SPI Pharma. A highly experienced international business executive with a proven track record in strategy development and execution, operational management, and innovation for Specialty Ingredients, Scott joins SPI Pharma after 29 years with BASF.

VEO Diagnostics announces the launch and sole distribution rights in the United States to the ACCEL ELISA ® COVID-19 kit, a serological microplate-based enzyme linked immunosorbent assay (ELISA) for the qualitative detection of total antibodies (includi

SEngine Precision Medicine , a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived tumor organoids, today announced that Chief Medical Officer Astrid L. Margossian, MD, PhD, will present at the Society for Functional Precision Medicine (SFPM) Virtual Monthly Seminar on October 14th at 11:30 am ET. Dr. Margossian is leading SEngine’s clinical validation initiatives for the PARIS ®

LTC ACO, the first long-term care sponsored Accountable Care Organization (“ACO”) in the United States and a subsidiary of Genesis HealthCare (Genesis) (NYSE:GEN), recently received a positive reconciliation and settlement under the Medicare Shared Savings Program (“MSSP”) for the 2019 performance year and as a result, generated shared savings for the second consecutive year. During 2019, the Company managed approximately 5,800 Medicare

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $40.00 per share pursuant to its existing shelf registration statement, for gross proceeds of $230.0 million. The number of shares issued at closing in

10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: w

Perdue Farms has been named the Gold winner in the Company Response of the Year During COVID-19 category in the tenth annual Consumer World Awards , which recognize consumer products, companies and people gl

Featuring an intuitive interface and automatic waveform capture, the new sensor eliminates the settings and manual adjustments oscilloscopes require